Sparrow Pharmaceuticals

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Sparrow Pharmaceuticals is developing new standards-of-care for both types of Cushing’s syndrome.

• Endogenous, caused by a excess of the natural steroid from a tumor. Our lead Phase 2 asset has clinical proof-of-concept to treat this rare disease.
• Exogenous, caused by steroid medicines such as prednisone. We have a Phase 2 asset to treat this condition, for which millions of patients who rely on long-term steroid prescription to control autoimmune diseases are at risk.
Speaker
photo
CEO/Founder
Sparrow Pharmaceuticals